Role of cyclooxygenase-2 in exacerbation of allergen-induced airway remodeling by multiwalled carbon nanotubes

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 4, 2013, Pages 525-535

  Sayers, Brian C ^a   Taylor, Alexia J ^a   Glista Baker, Ellen E ^a   Shipley Phillips, Jeanette K ^a   Dackor, Ryan T ^b   Edin, Matthew L ^b   Lih, Fred B ^b   Tomer, Kenneth B ^b   Zeldin, Darryl C ^b   Langenbach, Robert ^b   Bonner, James C ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Asthma; Carbon nanotubes; COX 2; Inflammation; Nanoparticles

Indexed keywords

CYCLOOXYGENASE 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 5; MESSENGER RNA; MULTI WALLED NANOTUBE; OVALBUMIN; PROSTAGLANDIN D2; THROMBOXANE B2;

AIRWAY REMODELING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; GOBLET CELL; IMMUNE RESPONSE; LUNG FIBROSIS; MALE; METAPLASIA; MOUSE; MUCUS CELL METAPLASIA; NONHUMAN; PATHOGENESIS; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; TH17 CELL; TH2 CELL; WILD TYPE;

AIRWAY REMODELING; ALLERGENS; ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINES; FEMALE; INFLAMMATION; MALE; MEMBRANE PROTEINS; METAPLASIA; MICE; MICE, INBRED C57BL; MUCUS; NANOTUBES, CARBON; OVALBUMIN; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84886500144     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0019OC     Document Type: Article

References (51)

1. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report. J Allergy Clin Immunol 2007;120:S94-S138.
2. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003;111: 215-225.
3. Al-Muhsen S, Johnson JR, Hamid Q. Remodeling in asthma. J Allergy Clin Immunol 2011;128:451-462.
4. Lemanske RF Jr, Busse WW. Asthma: clinical expression and molecular mechanisms. J Allergy Clin Immunol 2010;125:S95-S102.
5. Gavett SH, Koren HS. The role of particulate matter in exacerbation of atopic asthma. Int Arch Allergy Immunol 2001;124:109-112.
6. Peters A, Wichmann H, Tuch T, Heinrich J, Heyder J. Respiratory effects are associated with the number of ultrafine particles. Am J Respir Crit Care Med 1997;155:1376-1383.
7. Oberd'rster G, Oberd'rster E, Oberd'rster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005;113:823-839.
8. Bonner JC. Nanoparticles as a potential cause of pleural and interstitial lung disease. Proc Am Thorac Soc 2010;7:138-141.
9. Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol 2008;295:L400-L411.
10. Ryman-Rasmussen JP, Tewksbury EW, Moss OR, Cesta MF, Wong BA, Bonner JC. Inhaled multiwalled carbon nanotubes potentiate airway fibrosis in murine allergic asthma. Am J Respir Cell Mol Biol 2009;40: 349-358.
11. Inoue K-I, Koike E, Yanagisawa R, Hirano S, Nishikawa M, Takano H. Effects of multi-walled carbon nanotubes on a murine allergic airway inflammation model. Toxicol Appl Pharmacol 2009;237:306-316.
12. Wang X, Katwa P, Podila R, Chen P, Ke PC, Rao AM, Walters DM, Wingard CJ, Brown JM. Multi-walled carbon nanotube instillation impairs pulmonary function in C57BL/6 mice. Part Fibre Toxicol 2011;8:24.
13. Kabesch M, Schedel M, Carr D, Woitsch B, Fritzsch C, Weiland SK, von Mutius E. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. J Allergy Clin Immunol 2006;117:269-274.
14. Kim H-B, Kang M-J, Lee S-Y, Jin H-S, Kim J-H, Kim B-S, Jang S-O, Lee Y-C, Sohn M-H, Kim K-E, et al. Combined effect of tumour necrosis factor-alpha and interleukin-13 polymorphisms on bronchial hyperresponsiveness in Korean children with asthma. Clin Exp Allergy 2008;38:774-780.
15. London SJ. Gene-air pollution interactions in asthma. Proc Am Thorac Soc 2007;4:217-220.
16. Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol 2008;8:169-182.
17. Arima K, Umeshita-Suyama R, Sakata Y, Akaiwa M, Mao X-Q, Enomoto T, Dake Y, Shimazu S-I, Yamashita T, Sugawara N, et al. Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma. J Allergy Clin Immunol 2002;109: 980-987.
18. Kuperman D, Huang X, Koth L, Chang G, Dolganov G, Zhu Z, Elias J, Sheppard D, Erle D. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002;8:885-889.
19. Vladich FD, Brazille SM, Stern D, Peck ML, Ghittoni R, Vercelli D. IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. J Clin Invest 2005;115:747-754.
20. Pierzchalska M, Soja J, Woś M, Szabó Z, Nizankowska-Mogielnicka E, Sanak M, Szczeklik A. Deficiency of cyclooxygenases transcripts in cultured primary bronchial epithelial cells of aspirin-sensitive asthmatics. J Physiol Pharmacol 2007;58:207-218.
21. Trudeau J, Hu H, Chibana K, Chu HW, Westcott JY, Wenzel SE. Selective downregulation of prostaglandin E2-related pathways by the Th2 cytokine IL-13. J Allergy Clin Immunol 2006;117:1446-1454.
22. Stumm CL, Wettlaufer SH, Jancar S, Peters-Golden M. Airway remodeling in murine asthma correlates with a defect in PGE2 synthesis by lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2011;301:L636-L644.
23. Peebles RS, Hashimoto K, Morrow JD, Dworski R, Collins RD, Hashimoto Y, Christman JW, Kang K-H, Jarzecka K, Furlong J, et al. Selective cyclooxygenase-1 and-2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. Am J Respir Crit Care Med 2002;165:1154-1160.
24. Gavett SH, Madison SL, Chulada PC, Scarborough PE, Qu W, Boyle JE, Tiano HF, Lee CA, Langenbach R, Roggli VL, et al. Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J Clin Invest 1999;104:721-732.
25. Stokes Peebles RJ, Dworski R, Collins RD, Jarzecka K, Mitchell DB, Graham BS, Sheller JR. Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am J Respir Crit Care Med 2000;162:676.
26. Nakata J, Kondo M, Tamaoki J, Takemiya T, Nohara M, Yamagata K, Nagai A. Augmentation of allergic inflammation in the airways of cyclooxygenase-2- deficient mice. Respirology 2005;10:149-156.
27. Ryman-Rasmussen JP, Cesta MF, Brody AR, Shipley-Phillips JK, Everitt JI, Tewksbury EW, Moss OR, Wong BA, Dodd DE, Andersen ME, et al. Inhaled carbon nanotubes reach the subpleural tissue in mice. Nat Nanotechnol 2009;4:747-751.
28. Lee JK, Sayers BC, Chun K-S, Lao H-C, Shipley-Phillips JK, Bonner JC, Langenbach R. Multi-walled carbon nanotubes induce COX-2 and iNOS expression via MAP kinase-dependent and-independent mechanisms in mouse RAW264.7 macrophages. Part Fibre Toxicol 2012;9:14.
29. Ledford JG, Goto H, Potts EN, Degan S, Chu HW, Voelker DR, Sunday ME, Cianciolo GJ, Foster WM, Kraft M, et al. SP-A preserves airway homeostasis during Mycoplasma pneumoniae infection in mice. J Immunol 2009;182:7818-7827.
30. Card JW, Voltz JW, Carey MA, Bradbury JA, Degraff LM, Lih FB, Bonner JC, Morgan DL, Flake GP, Zeldin DC. Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. Am J Respir Cell Mol Biol 2007;37:300-308.
31. Brass DM, Savov JD, Gavett SH, Haykal-Coates N, Schwartz DA. Subchronic endotoxin inhalation causes persistent airway disease. Am J Physiol Lung Cell Mol Physiol 2003;285:L755-L761.
32. Li H, Bradbury JA, Dackor RT, Edin ML, Graves JP, DeGraff LM, Wang PM, Bortner CD, Maruoka S, Lih FB, et al. Cyclooxygenase-2 regulates Th17 cell differentiation during allergic lung inflammation. Am J Respir Crit Care Med 2011;184:37-49.
33. Newman JW,Watanabe T,Hammock BD. The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res 2002;43:1563-1578.
34. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-2261.
35. Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol 2012;130:829-842.
36. Lajoie S, Lewkowich IP, Suzuki Y, Clark JR, Sproles AA, Dienger K, Budelsky AL, Wills-Karp M. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nature Publishing Group 2010;11:928-935.
37. Wang Y-H, Wills-Karp M. The potential role of interleukin-17 in severe asthma. Curr Allergy Asthma Rep 2011;11:388-394.
38. Carey MA, Germolec DR, Bradbury JA, Gooch RA, Moorman MP, Flake GP, Langenbach R, Zeldin DC. Accentuated T helper Type 2 airway response after allergen challenge in cyclooxygenase-12/2 but not cyclooxygenase-22/2 mice. Am J Respir Crit CareMed 2003;167:1509-1515.
39. Miotto D, Christodoulopoulos P, Olivenstein R, Taha R, Cameron L, Tsicopoulos A, Tonnel AB, Fahy O, Lafitte JJ, Luster AD, et al. Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in Th1-and Th2-mediated lung diseases. J Allergy Clin Immunol 2001;107:664-670.
40. Wark PA, Bucchieri F, Johnston SL, Gibson PG, Hamilton L, Mimica J, Zummo G, Holgate ST, Attia J, Thakkinstian A, et al. IFN-gamma-induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations. J Allergy Clin Immunol 2007;120:586-593.
41. Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy: J of Human Pharmacol Drug Therapy 1997;17:3S-12S.
42. Park GY, Christman JW. Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. Am J Physiol Lung Cell Mol Physiol 2006;290:L797-L805.
43. Shiraishi Y, Asano K, Niimi K, Fukunaga K, Wakaki M, Kagyo J, Takihara T, Ueda S, Nakajima T, Oguma T, et al. Cyclooxygenase-2/prostaglandin D2/CRTH2 pathway mediates double-stranded RNA-induced enhancement of allergic airway inflammation. J Immunol 2008; 180:541-549.
44. Stebbins KJ, Broadhead AR, Correa LD, Scott JM, Truong YP, Stearns BA, Hutchinson JH, Prasit P, Evans JF, Lorrain DS. Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol 2010;638:142-149.
45. Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, Sugimoto Y, Kobayashi T, Ushikubi F, Aze Y, et al. Prostaglandin D2 as a mediator of allergic asthma. Science 2000;287:2013-2017.
46. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007;6:313-325.
47. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor 1. J Exp Med 2001;194:809-822.
48. Brewer JP, Kisselgof AB, Martin TR. Genetic variability in pulmonary physiological, cellular, and antibody responses to antigen in mice. Am J Respir Crit Care Med 1999;160:1150-1156.
49. Kirtikara K, Morham SG, Raghow R, Laulederkind SJ, Kanekura T, Goorha S, Ballou LR. Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells. J Exp Med 1998;187:517-523.
50. Sandee D, Sivanuntakorn S, Vichai V, Kramyu J, Kirtikara K. Upregulation of microsomal prostaglandin E synthase-1 in COX-1 and COX-2 knock-out mouse fibroblast cell lines. Prostaglandins Other Lipid Mediat 2009;88:111-116.
51. Matsumoto A, Hiramatsu K, Li Y, Azuma A, Kudoh S, Takizawa H, Sugawara I. Repeated exposure to low-dose diesel exhaust after allergen challenge exaggerates asthmatic responses in mice. Clin Immunol 2006;121:227-235.